Добірка наукової літератури з теми "Dysfonction chronique de l'allogreffe"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Dysfonction chronique de l'allogreffe".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "Dysfonction chronique de l'allogreffe":
Arsever, Sara, and Jean Perdrix. "Migraine chronique et dysfonction érectile." Revue Médicale Suisse 18, no. 781 (2022): 962. http://dx.doi.org/10.53738/revmed.2022.18.781.962.
Hedhli, A., A. Slim, S. Cheikhrouhou, S. Toujani, M. Mjid, Y. Ouahchi, and S. Merai. "Dysfonction érectile et bronchopneumopathie chronique obstructive." Revue des Maladies Respiratoires Actualités 12, no. 1 (January 2020): 100–101. http://dx.doi.org/10.1016/j.rmra.2019.11.207.
Hubert, F., K. Dahan, J. P. Cosyns, O. Devuyst, and Y. Pirson. "Dysfonction rénale discrète et histoire familiale de néphropathie chronique." Néphrologie & Thérapeutique 8, no. 1 (February 2012): 66–67. http://dx.doi.org/10.1016/j.nephro.2011.07.424.
Hazzan, M., F. Glowacki, A. Lionet, F. Provot, and C. Noël. "Stratégies immunosuppressives et dysfonction chronique du greffon en transplantation rénale." Néphrologie & Thérapeutique 4 (October 2008): S208—S213. http://dx.doi.org/10.1016/s1769-7255(08)74237-8.
Cheddani, L., I. Etienne, C. Laurent, A. François, M. Hanoy, L. Lebourg, F. Leroy, et al. "Bélatacept et dysfonction chronique de greffon : traitement de dernière chance ?" Néphrologie & Thérapeutique 12, no. 5 (September 2016): 284. http://dx.doi.org/10.1016/j.nephro.2016.07.372.
Dao, M., L. Lecru, S. Ferlicot, S. Vandermeersch, A. Durrbach, C. Chatziantoniou, and H. François. "Le rôle des récepteurs cannabinoïdes dans la dysfonction chronique de l’allogreffe." Néphrologie & Thérapeutique 14, no. 5 (September 2018): 408. http://dx.doi.org/10.1016/j.nephro.2018.07.357.
Boussoffara, L., N. Boudawara, H. Regaieg, H. Gamra, F. Abroug, and J. Knani. "138 La dysfonction ventriculaire gauche dans la bronchopneumopathie chronique obstructive stable." Revue des Maladies Respiratoires 24 (January 2007): 54. http://dx.doi.org/10.1016/s0761-8425(07)72514-7.
Kobza and Erne. "Tachyarrythmien – wenn Geschwindigkeit krank macht." Praxis 92, no. 1 (January 1, 2003): 6–17. http://dx.doi.org/10.1024/0369-8394.92.1.6.
Phé, V., M. Roupret, K. Ferhi, B. Barrou, O. Cussenot, O. Traxer, F. Haab, and S. Beley. "Étiologie et prise en charge de la dysfonction érectile chez l’insuffisant rénal chronique." Progrès en Urologie 19, no. 1 (January 2009): 1–7. http://dx.doi.org/10.1016/j.purol.2008.07.003.
El Alaoui Ismaili, F., S. Fellahi, A. Chemlal, I. Karimi, I. Haddiya, and Y. Bentata. "Quel est l’impact réel de la dépression sur La dysfonction érectile en hémodialyse chronique ?" Néphrologie & Thérapeutique 10, no. 5 (September 2014): 326. http://dx.doi.org/10.1016/j.nephro.2014.07.094.
Дисертації з теми "Dysfonction chronique de l'allogreffe":
Dao, Myriam. "Le blocage du récepteur cannabinoïde de type 1 : une nouvelle piste thérapeutique dans la maladie rénale chronique." Electronic Thesis or Diss., Sorbonne université, 2021. https://accesdistant.sorbonne-universite.fr/login?url=https://theses-intra.sorbonne-universite.fr/2021SORUS389.pdf.
Some studies suggest that the cannabinoid receptor type 1 (CB1R) inhibition could be a new therapeutic toolbox in chronic kidney disease (CKD), especially in metabolic nephropathies. We aimed that CB1R promotes renal fibrogenesis, regardless of its cause. Its inhibition, genetic or pharmacological, could protect the kidney against the progression of CKD. We supported our hypothesis by a threefold approach: translational, experimental in mice and in vitro with culture cells of proximal tubular epithelial cells and myofibroblasts. Whereas CB1R expression was low in normal kidney grafts, it was highly expressed during chronic allograft dysfunction, especially in tubular cells. CB1R expression significantly increased early on after transplantation and correlated with renal fibrosis at M3. In vitro, we found that rimonabant, a CB1R antagonist, blunted collagen synthesis by tubular cells. We performed an experimental mouse model of CKD induced by ischemia-reperfusion (I/R-CKD). In this model, the global genetic or pharmacological inhibition of CB1R prevented CKD and significantly reduced interstitial fibrosis. In vitro, pharmacological inhibition of CB1R reduced collagen synthesis by myofibroblasts. Unexpectedly, the deletion of CB1R restricted to renal tubular cells worsened CKD in I/R-CKD. The protective effect of the global inhibition of CB1R is therefore probably mediated by a predominant effect on myofibroblasts.Thus, we demonstrated that the pharmacological blockade of CB1R could be a new therapeutic toolbox in CKD, regardless of its origin
Brugat, Thibaut. "Dysfonction télomérique dans les cellules résistantes de leucémie lymphocytaire chronique (LLC)." Paris 5, 2010. http://www.theses.fr/2010PA05P602.
CLL is a highly heterogeneous disease and remains incurable. The biological researches have identified the mean telomere length (protective ends of chromosome) as a new prognostic factor because the malignant cells of the progressive form of the disease have shorter telomeres than the indolent form. In parallel it has been demonstrated in our lab that leukemic cells from CLL patients may be resistant (CLL-R) or sensitive (CLL-S) in vitro to DNA damage (DSB) induced apoptosis. This difference seems to be correlated with their sensitivity to first-line treatment and is associated with deregulation of the non homologous end-joining system (NHEJ). The objective of this study was to know if the telomeric dysfunction is associated to a resistance to DSB and to better caracterise this dysfunction in CLL cells. The results show that the mean telomere length is twofold shorter in the CLL-R as compared to CLL-S and that this shortening is associated with an altered telomere structure which may limit the action of elongation systems. We also demonstrated that the presence of short telomeres in CLL-R cells is accompanied by i) a shortening of the telomeric single-stranded portion, ii) telomeres recognition by factors implicated in DSB signalling and repair by the NHEJ system, and iii) a loss of telomeric sequences associated with chromosomal abnormalities which are hallmarks of poor prognosis. Altogether, these results suggest that telomere dysfunction is not only a biological characteristic of the progressive form of CLL but may also be responsible for its development and /or its appearance
Amabile, Nicolas. "Microparticules endothéliales circulantes et dysfonction endothéliale in vivo." Paris 7, 2010. http://www.theses.fr/2010PA077268.
Microparticles (MPs) are shed membrane vesicles released by different cells after activation or apoptosis. This work investigates the relationships between circulating endothelial microparticles (EMPs) levels and endothelial fonction in different clinical situations in human beings. We first showed a strong relationship between EMPs levels, arterial stiffness and flow-mediated dilation (FMD) in end-stage renal failure disease (ESRF) patients. Moreover, the EMPs that were isolated ex vivo from these patients' plasma experimentally induced an endothelial dysfunction by reducing nitric oxide synthesis. Furthermore, we showed an inverse relationship between EMPs levels and value of shear stress applied to these ESRF patients' endothelium. Then, we studied subjects with pulmonary hypertension (PH): we found an increase in EMPs levels compared to normal controls and a strong correlation between CD31+/41-, CD 144+ EMPs levels and several hemodynamic parameters of disease severity. We also investigated the impact of an acute tobacco second hand smoke exposure on healthy volunteers endothelium: this acute endothelial injury induced a quick and sustained increased in EMPs levels, associated with a transient decrease in FMD values, that were subsequently followed by an increase in the number of circulating endothelial progenitor cells. Finally, we focused on the prognostic value of EMPs levels on clinical outcome: we found that elevated values of CD62e+ EMPs predicted poor outcome in PH patients, whereas increased levels of CD31+/41- EMPs were associated with increased incidence major cardiovascular events in ESRF subjects
D'Amours, Martin. "Interactions des facteurs endothéliaux dans la dysfonction endothéliale en insuffisance rénale chronique." Thesis, Université Laval, 2007. http://www.theses.ulaval.ca/2007/24559/24559.pdf.
Souweine, Jean Sébastien. "Dysfonction musculaire en hémodialyse : de la sarcopénie à la myopathie urémique." Thesis, Montpellier, 2019. http://www.theses.fr/2019MONTT040.
Muscle dysfunction, a common feature in chronic haemodialysis patients, is associated with an increased risk of mortality independently of the disease severity, like sarcopenia in elderly patients. Despite similarities between the two situations, muscle dysfunction in chronic haemodialysis patients must be distinguished from sarcopenia. Some molecular abnomalities observed, such as the transition from slow to fast-fibre in muscle, appear to be different from those described during aging. This thesis comprises four studies which aim to identify and characterize the muscle dysfunction in chronic haemodialysis patients. In the first study, we developed a reliable and reproducible tool allowing the measurement of quadriceps muscle strength at the bedside. The second one showed that clinical and biological factors associated with a decrease in muscle strength were different from those associated with a decrease in muscle mass. In this study we were also able to identify patients with a decrease in muscle strength without a decrease in muscle mass, which characterizes dynapenic patients. The prognosis of these patients was studied in the third study. The risk of death was similar in these patients compared to sarcopenic patients, even though dynapenic patients were younger with fewer comorbidities.. This work also showed that muscle strength is a better prognosis marker than muscle mass. Finally, in the fourth study, we showed in hemodialysis patients on the waiting list for a kidney transplant, that a true renal insufficiency-induced myopathy with specific histological characteristics could exist. These characteristics are compatible with the decrease in endurance observed in this population. Thus, starting from the universally recognized clinical criterion of muscle mass, we have evolved towards the exploration of strength and endurance. Finally, this work provides some elements that confirm the existence of muscle abnormalities specific to chronic renal failure
Hazzan, Marc. "Dysfonction chronique du greffon en transplantation rénale : stratégies immunosuppressives et approche anti-inflammatoire expérimentale." Lille 2, 2006. http://www.theses.fr/2006LIL2S016.
Chronic allograft dysfunction (CAD) is a chronic inflammatory state inside the graft, causally related to immunological and non immunological injuries. Despite significant improvements in immunosuppressive regimens that led to better results in the short term, CAD remains a major cause of late graft lost in renal transplantation. The clinical part of this work was to evaluate the efficiency and safety of mycophenolate mofetil (MMF) in a strategy of cyclosporine (CsA) withdrawal, for the prevention of acute rejection and nephrotoxicity of calcineurin inhibitors, two of the strongest risk factors for CAD. In a retrospective study we compared azathioprine to mycophenolate mofetil associated with CsA: MMF+CsA reduced the incidence of acute rejection and weakened the deleterious consequences of acute rejection, resulting in significantly increased 3-year graft survival rates in patients who had experienced one or more acute rejection episodes during the first 6 months post graft. In a randomized, open-labelled study to evaluate early (3 months) withdrawal of CsA under MMF and prednisone in low immunological risk recipients, we demonstrated a significant improvement of the renal function at 1 and 2 years after CsA discontinuation. However, a higher proportion of the recipients withdrawn from CsA experienced acute rejection, as compared with patients withdrawn from MMF and maintained under CsA and prednisone. Pharmacokinetics of MMF and borderline histological changes in the 3-month graft biopsy were identified as 2 independent predictors of acute rejection after CsA withdrawal. The 1-year systematic graft biopsy revealed that a significant number of patients withdrawn from CsA developed peritubular C4d deposits, independently of the occurrence of early acute rejection episodes. However, neither 1-year Chronic Allograft Damage Index nor 2-year graft function were suggestive of a progression towards chronic rejection in these patients. Further follow-up as well as specific investigations (e. G. HLA antibodies) are needed to clarify this result, which questions the prognostic value of C4d deposits on protocol biopsies in stable patients. Because both immunological and non immunological injuries contribute to a chronic inflammatory process, we evaluated the impact of different anti-inflammatory and/or immunomudulatory drugs on the progression of CAD. Pentoxifylline, statins, and PPAR (Peroxisome Proliferator-Activated Receptors) agonists were tested because of their known pleiotropic effects and their safety in clinical practice. In a murine model of skin allograft, neither pentoxifylline nor statins modified the course of chronic rejection in this model. The PPAR ligand fenofibrate paradoxically exacerbated fibrosis in allogeneic and syngeneic skin grafts when administrated immediately after the graft. These data suggest that activation of PPAR, which is transiently expressed after a cutaneous lesion, may interfere with wound healing in this model. Prevention of CAD can partly rely on early modifications of the immunosuppressive regimen to avoid long term nephrotoxicity of calcineurin inhibitors, but this strategy carries a significant risk of acute rejection, and CsA elimination cannot be recommended for all patients. This risk can be minimized in carefully selected recipients according to the early events post graft, pharmacokinetics of the immunosuppressive drugs, and histological results at 3 months. However, the nephrotoxicity of calcineurin inhibitors is only one among multiple factors involved in the chronic inflammatory process leading to CAD. Non-specific anti-inflammatory treatment in association with immunosuppressive drugs could slow down progression of graft failure. An experimental approach can help to select active molecules before initiating clinical trials that will require high numbers of patients and a prolonged follow-up
Durand, Maxim. "Etude de la régulation lymphocytaire T dans deux modèles de transplantation rénale et pulmonaire." Thesis, Nantes, 2018. http://www.theses.fr/2018NANT1001/document.
Transplantation is nowadays systematically associated with the administration of immunosuppressive treatments inhibiting the allo-immune response toward the graft to prevent the rejection by the recipient's immune system. However, these heavy treatments have several deleterious effects and are not able to control longterm chronic rejection development. Thus, the objective of this PhD work, based on two distinct clinical situations, is part of two priority axes of transplant research: (1) identify early predictive markers of long-term lung allograft dysfunction and (2) decipher the mechanisms involved in the acceptance of kidney allograft in operational tolerance. We first investigated the mechanisms of graft acceptance in kidney transplanted patients with a functional graft in the absence of immunosuppressive therapy. We identified in these patients a greater proportion of circulating memory regulatory T lymphocytes, with an increased ability to degrade extracellular ATP, a pro-inflammatory mediator, and favour a protolerogenic environment. Thus, this mechanism, not efficient in stable patients under treatments, could participate in the inhibition of the allo-immune response leading to maintaining a functional kidney graft in the absence of immunosuppression. In a second time, we interested in the prediction of chronic rejection occurrence in lung transplanted patients. We report that the early posttransplant regulatory T lymphocyte profile is modified in patients who will develop chronic rejection in the 3 years. Thus, monitoring this predictive biomarker could allow a better identification of patients at risk of rejection
Delample, Delphine. "La dysfonction musculaire périphérique dans la bronchopneumopathie chronique obstructive : mécanismes cellulaires et implication du stress oxydant." Montpellier 1, 2008. http://www.theses.fr/2008MON1T032.
D'Amours, Martin. "Dysfonction endothéliale et insuffisance rénale chronique, rôle de l'angiotensine II, de l'endothéline-1 et du monoxyde d'azote." Thesis, National Library of Canada = Bibliothèque nationale du Canada, 1998. http://www.collectionscanada.ca/obj/s4/f2/dsk2/tape17/PQDD_0025/MQ38061.pdf.
Pain, Mallory. "Un nouveau biomarqueur de la dysfonction chronique du greffon pulmonaire : du modèle in vitro à la cohorte COLT." Nantes, 2014. http://archive.bu.univ-nantes.fr/pollux/show.action?id=7a8ee065-2a60-42d6-b914-3806664fe12b.
Chronic lung allograft dysfunction (CLAD) is the major limitation to lung transplantation, with the most common phenotype being bronchiolitis obliterans (BO). BO is characterized by an irreversible airflow obstruction after an aberrant airway remodeling process. Bronchial epithelial cells (BEC) seem to play a key role in this process through epithelial to mesenchymal transition (EMT). The aim of this study was to 1) set up an in vitro model of allogeneic co-culture 2) test the impact of allogeneic context on EMT 3) identify new predictive biomarkers of BO. I have developed a new in vitro co-culture model between BEC and allogeneic activated T cells and/or monocytes. Detection of CCL2, CCL3, CCL4 and CXCL-10 in culture supernatants shows the relevance of the model. I have demonstrated that immune cells in synergywith TGF-ß favors MMP-9 secretion. Furthermore, I have demonstrated the role of CCL2/CCR2 in this secretion, suggesting CCR2 as a potentiel therapeutic target. Finally, thanks to COLT cohort, I have validated plasma MMP-9 as a predictive biomarker of BO. This new in vitro model suggests the implication of allogenicity in EMT during epithelium remodeling by the induction of MMP and propose a link between CCL2 and MMP-9. It appears as a relevant tool for biomarker discovery as presented here with MMP9. Plasmatic MMP-9 maybe a valuable biomarker for BO